

## Special Issue

# Advances in B-Cell Lymphoma: From Diagnostics to Cure

### Message from the Guest Editors

We are pleased to announce the Special Issue **"Advances in B-Cell Lymphoma: From Diagnostics to Cure"** in the journal *Cancers*. B-cell lymphomas represent the most common subtype of non-Hodgkin lymphoma, accounting for over 60% of all hematologic malignancies. Recent years have witnessed significant progress in molecular classification, prognostic evaluation, and innovative treatment strategies. This issue aims to consolidate the latest advances in the field. We welcome original research and review articles on topics including molecular profiling, novel biomarkers, the tumor microenvironment, targeted and immunotherapies, and cellular therapies. We invite contributions from researchers and clinicians worldwide to help advance the understanding and management of B-cell lymphoma.

---

### Guest Editors

Prof. Dr. Leo I. Gordon

Hematology Oncology Division, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

Dr. Megan E. Melody

Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

---

### Deadline for manuscript submissions

30 June 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/203091](https://mdpi.com/si/203091)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)